Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

DND1 maintains germline stem cells via recruitment of the CCR4-NOT complex to target mRNAs.

Yamaji M, Jishage M, Meyer C, Suryawanshi H, Der E, Yamaji M, Garzia A, Morozov P, Manickavel S, McFarland HL, Roeder RG, Hafner M, Tuschl T.

Nature. 2017 Mar 23;543(7646):568-572. doi: 10.1038/nature21690. Epub 2017 Mar 15.

2.

Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.

Neil S, Huh J, Baronas V, Li X, McFarland HF, Cherukuri M, Mitchell JB, Quandt JA.

Brain Behav Immun. 2017 May;62:332-343. doi: 10.1016/j.bbi.2017.02.018. Epub 2017 Feb 24.

3.

Introduction to the Special Issue.

McFarland H, Reich DS, Jacobson S.

J Neuroimmunol. 2017 Mar 15;304:1. doi: 10.1016/j.jneuroim.2017.01.022. Epub 2017 Feb 3. No abstract available.

4.

PAR-CLIP and streamlined small RNA cDNA library preparation protocol for the identification of RNA binding protein target sites.

Benhalevy D, McFarland HL, Sarshad AA, Hafner M.

Methods. 2017 Apr 15;118-119:41-49. doi: 10.1016/j.ymeth.2016.11.009. Epub 2016 Nov 18.

PMID:
27871973
5.

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, Klawiter EC, Mainero C, Massacesi L, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS; NAIMS Cooperative.

Nat Rev Neurol. 2016 Dec;12(12):714-722. doi: 10.1038/nrneurol.2016.166. Epub 2016 Nov 11. Review.

PMID:
27834394
6.

Computed Tomography Morphometrics and Pulmonary Intolerance in Endometrial Cancer Robotic Surgery.

Abdelbadee AY, Paspulati RM, McFarland HD, Bedaiwy MA, Ciancibello L, Anderson G, Zanotti KM.

J Minim Invasive Gynecol. 2016 Nov - Dec;23(7):1075-1082. doi: 10.1016/j.jmig.2016.07.014. Epub 2016 Jul 20.

PMID:
27449691
7.

Computerized Tomography Adiposity Morphometrics: A Novel Approach to Predict Pulmonary Intolerance in Endometrial Cancer Patients Undergoing Robotic Pelvic Surgery (RPS).

Abdelbadee AY, Paspulati RM, McFarland HD, Bedaiwy MA, Ciancibello LM, Anderson G, Zanotti KM.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S9-S10. doi: 10.1016/j.jmig.2015.08.032. Epub 2015 Oct 15. No abstract available.

PMID:
27679372
8.

Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.

Stone LA, Cutter GR, Fisher E, Richert N, McCartin J, Ohayon J, Bash C, McFarland H.

J Neuroimaging. 2016 May;26(3):296-302. doi: 10.1111/jon.12321. Epub 2015 Dec 21.

PMID:
26686343
9.

First-Principles Investigation of Nanopore Sequencing Using Variable Voltage Bias on Graphene-Based Nanoribbons.

McFarland HL, Ahmed T, Zhu JX, Balatsky AV, Haraldsen JT.

J Phys Chem Lett. 2015 Jul 2;6(13):2616-21. doi: 10.1021/acs.jpclett.5b01014. Epub 2015 Jun 22.

PMID:
26266743
10.

Rescue of CD8+ T cell vaccine memory following sublethal γ irradiation.

McFarland HI, Berkson JD, Lee JP, Elkahloun AG, Mason KP, Rosenberg AS.

Vaccine. 2015 Jul 31;33(32):3865-72. doi: 10.1016/j.vaccine.2015.06.070. Epub 2015 Jun 26.

11.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
12.

The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.

Borges IT, Shea CD, Ohayon J, Jones BC, Stone RD, Ostuni J, Shiee N, McFarland H, Bielekova B, Reich DS.

Mult Scler Relat Disord. 2013 Apr 1;2(2):133-140.

13.

Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination.

Yuen TJ, Johnson KR, Miron VE, Zhao C, Quandt J, Harrisingh MC, Swire M, Williams A, McFarland HF, Franklin RJ, Ffrench-Constant C.

Brain. 2013 Apr;136(Pt 4):1035-47. doi: 10.1093/brain/awt024. Epub 2013 Mar 21.

14.

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.

Bradbury RH, Acton DG, Broadbent NL, Brooks AN, Carr GR, Hatter G, Hayter BR, Hill KJ, Howe NJ, Jones RD, Jude D, Lamont SG, Loddick SA, McFarland HL, Parveen Z, Rabow AA, Sharma-Singh G, Stratton NC, Thomason AG, Trueman D, Walker GE, Wells SL, Wilson J, Wood JM.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. doi: 10.1016/j.bmcl.2013.02.056. Epub 2013 Feb 21.

PMID:
23466225
15.

CNS vasculitis in a patient with MS on daclizumab monotherapy.

Ohayon J, Oh U, Richert N, Martin J, Vortmeyer A, McFarland H, Bielekova B.

Neurology. 2013 Jan 29;80(5):453-7. doi: 10.1212/WNL.0b013e31827f0f42. Epub 2013 Jan 9.

16.

Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.

Quandt JA, Huh J, Baig M, Yao K, Ito N, Bryant M, Kawamura K, Pinilla C, McFarland HF, Martin R, Ito K.

J Immunol. 2012 Sep 15;189(6):2897-908. doi: 10.4049/jimmunol.1103087. Epub 2012 Aug 10.

17.

Regulatory T cells in γ irradiation-induced immune suppression.

McFarland HI, Puig M, Grajkowska LT, Tsuji K, Lee JP, Mason KP, Verthelyi D, Rosenberg AS.

PLoS One. 2012;7(6):e39092. doi: 10.1371/journal.pone.0039092. Epub 2012 Jun 19.

18.

Comment on "Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation".

Bielekova B, McFarland H.

Ann Neurol. 2012 Jan;71(1):148-9. doi: 10.1002/ana.22547. No abstract available.

PMID:
22275261
19.

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Bielekova B, Richert N, Herman ML, Ohayon J, Waldmann TA, McFarland H, Martin R, Blevins G.

Neurology. 2011 Nov 22;77(21):1877-86. doi: 10.1212/WNL.0b013e318239f7ef. Epub 2011 Nov 9.

20.

The importance of clinical trials in unraveling the mysteries of multiple sclerosis.

McFarland H.

J Neuroimmunol. 2011 Feb;231(1-2):3-6. doi: 10.1016/j.jneuroim.2010.12.010. Review.

PMID:
21300410
21.

T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis.

Bagnato F, Salman Z, Kane R, Auh S, Cantor FK, Ehrmantraut M, Gallo A, Ikonomidou VN, Ohayon J, Pellicano C, Stern SK, McFarland HF.

Mult Scler. 2010 Oct;16(10):1203-12. doi: 10.1177/1352458510377223. Epub 2010 Aug 10.

PMID:
20699284
22.

Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis.

Bomboi G, Ikonomidou VN, Pellegrini S, Stern SK, Gallo A, Auh S, Evangelou IE, Agarwal J, Pellicano C, Ohayon JM, Cantor FK, Ehrmantraut M, McFarland HF, Kane RL, Bagnato F.

J Neuroimaging. 2011 Apr;21(2):e57-63. doi: 10.1111/j.1552-6569.2010.00488.x.

PMID:
20626570
23.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.

PMID:
20610349
24.

Relationship of cortical atrophy to fatigue in patients with multiple sclerosis.

Pellicano C, Gallo A, Li X, Ikonomidou VN, Evangelou IE, Ohayon JM, Stern SK, Ehrmantraut M, Cantor F, McFarland HF, Bagnato F.

Arch Neurol. 2010 Apr;67(4):447-53. doi: 10.1001/archneurol.2010.48.

PMID:
20385911
25.

Ring and nodular multiple sclerosis lesions: a retrospective natural history study.

Davis M, Auh S, Riva M, Richert ND, Frank JA, McFarland HF, Bagnato F.

Neurology. 2010 Mar 9;74(10):851-6. doi: 10.1212/WNL.0b013e3181d31df5.

26.

Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.

McFarland HF.

Ann Indian Acad Neurol. 2009 Oct;12(4):254-63. doi: 10.4103/0972-2327.58284.

27.

Examination of the role of MRI in multiple sclerosis: a problem orientated approach.

McFarland HF.

Results Probl Cell Differ. 2010;51:287-301. doi: 10.1007/400_2009_33. Review.

PMID:
19960380
28.

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Bielekova B, Richert N, Howard T, Packer AN, Blevins G, Ohayon J, McFarland HF, Stürzebecher CS, Martin R.

Mult Scler. 2009 Oct;15(10):1206-14. doi: 10.1177/1352458509345903. Epub 2009 Sep 23.

29.

Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: observations from a post-mortem 3 Tesla imaging study.

Bagnato F, Yao B, Cantor F, Merkle H, Condon E, Montequin M, Moore S, Quezado M, Tkaczyk D, McFarland H.

J Neurol Sci. 2009 Jul 15;282(1-2):80-5. doi: 10.1016/j.jns.2009.03.021. Epub 2009 Apr 23.

30.

Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T.

Tovar-Moll F, Evangelou IE, Chiu AW, Richert ND, Ostuni JL, Ohayon JM, Auh S, Ehrmantraut M, Talagala SL, McFarland HF, Bagnato F.

AJNR Am J Neuroradiol. 2009 Aug;30(7):1380-6. doi: 10.3174/ajnr.A1564. Epub 2009 Apr 15.

31.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

32.

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S.

Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.

33.

Skin allograft rejection.

McFarland HI, Rosenberg AS.

Curr Protoc Immunol. 2009 Feb;Chapter 4:Unit 4.4. doi: 10.1002/0471142735.im0404s84.

PMID:
19235769
34.

Alemtuzumab versus interferon beta-1a: implications for pathology and trial design.

McFarland HF.

Lancet Neurol. 2009 Jan;8(1):26-8. doi: 10.1016/S1474-4422(08)70280-1. No abstract available.

PMID:
19081510
35.

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.

Chiu AW, Richert N, Ehrmantraut M, Ohayon J, Gupta S, Bomboi G, Gaindh D, Cantor FK, Frank JA, McFarland HF, Bagnato F.

Arch Neurol. 2009 Jan;66(1):39-43. doi: 10.1001/archneur.66.1.noc80047. Epub 2008 Nov 10.

PMID:
19001157
36.

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.

Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, McFarland HM, McGregor A, Moss L, Rudge DA, Simpson PB, Swain ML, Tam KY, Tucker JA, Walker M.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6369-73. doi: 10.1016/j.bmcl.2008.10.102. Epub 2008 Oct 25.

PMID:
18996007
37.

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

Gaindh D, Jeffries N, Ohayon J, Richert ND, Pellicano C, Frank JA, McFarland H, Bagnato F.

Expert Opin Biol Ther. 2008 Dec;8(12):1823-9. doi: 10.1517/14712590802510629 .

38.

Different development of myelin basic protein agonist- and antagonist-specific human TCR transgenic T cells in the thymus and periphery.

Kawamura K, Yao K, Shukaliak-Quandt JA, Huh J, Baig M, Quigley L, Ito N, Necker A, McFarland HF, Muraro PA, Martin R, Ito K.

J Immunol. 2008 Oct 15;181(8):5462-72.

39.

Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH.

Mult Scler. 2008 Nov;14(9):1157-74. doi: 10.1177/1352458508096878. Epub 2008 Sep 19.

40.

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.

Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF, Wolinsky JS.

Mult Scler. 2008 Jul;14(6):770-8. doi: 10.1177/1352458507088104. Epub 2008 Jun 5.

41.

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS.

Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d.

PMID:
18362273
42.

The B cell--old player, new position on the team.

McFarland HF.

N Engl J Med. 2008 Feb 14;358(7):664-5. doi: 10.1056/NEJMp0708143. No abstract available.

PMID:
18272890
43.

Multiple sclerosis: a complicated picture of autoimmunity.

McFarland HF, Martin R.

Nat Immunol. 2007 Sep;8(9):913-9. Review.

PMID:
17712344
44.

A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.

Chiu AW, Ehrmantraut M, Richert ND, Ikonomidou VN, Pellegrini S, McFarland HF, Frank JA, Bagnato F.

Clin Exp Immunol. 2007 Oct;150(1):61-7. Epub 2007 Jul 30.

45.

In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis.

Bagnato F, Butman JA, Gupta S, Calabrese M, Pezawas L, Ohayon JM, Tovar-Moll F, Riva M, Cao MM, Talagala SL, McFarland HF.

AJNR Am J Neuroradiol. 2006 Nov-Dec;27(10):2161-7.

46.

Natalizumab and immune cells.

McFarland HF, Jacobson S.

Arch Neurol. 2006 Oct;63(10):1366-7. No abstract available.

PMID:
17030649
47.

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6. Epub 2006 Apr 3.

48.

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis.

Richert ND, Howard T, Frank JA, Stone R, Ostuni J, Ohayon J, Bash C, McFarland HF.

Neurology. 2006 Feb 28;66(4):551-6.

PMID:
16505310
49.

Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis.

Bagnato F, Butman JA, Mora CA, Gupta S, Yamano Y, Tasciyan TA, Solomon JM, Santos WJ, Stone RD, McFarland HF, Jacobson S.

J Neurovirol. 2005 Dec;11(6):525-34.

PMID:
16338746
50.

Supplemental Content

Loading ...
Support Center